


A novel IgA therapeutic platform

Mucosal surfaces are critical sites for pathogen entry and cancer development, yet remain difficult to target and protect with conventional antibodies such as IgG. IgA can naturally reach and work at these surfaces in ways IgG cannot, but lacks IgG's durability. Burnet's technology combines the advantages of both.

Engineering next-generation IgA therapeutics

Unlike IgG, IgA is naturally transported across mucosal barriers into secretions, where it can provide local immune protection and engage distinct effector mechanisms. Burnet's platform combines these specialised IgA functions with IgG-like durability, creating therapeutics suitable for multiple delivery approaches.

Demonstrated to enhance SARS-CoV-2 neutralisation, the platform has potential across respiratory diseases including RSV, TB and influenza, with broader applications in mucosal diseases, including oncology.




Burnet's patented technology

Burnet's researchers are global leaders in understanding immune response to hepatitis C and SARS-CoV-2 infection. Burnet has developed novel assays and technology for measuring IgA. Our technology:

- ✓ enables the development of IgA-based therapeutic antibodies
- ✓ offers the ability to understand the role of different forms of IgA in immune responses to pathogens or vaccine candidates.

Burnet has the research expertise and commercial track record to bring novel dIgA therapies to address some of the world's most prevalent diseases.

From IgA engineering to *in vivo* proof of concept



End-to-end capabilities from antibody design and engineering through functional screening and preclinical validation.

ISO 9001: Highest quality, industry-ready R&D partner

Our ISO 9001 certification gives our industry partners, funders and study participants confidence that we conduct our research in an ethical, robust and reproducible way that meets the highest international standards.



- Antibody isotype engineering into IgA, dimeric and secretory IgA formats
- Bispecific and multi-specific IgA design for enhanced targeting and functional activity
- Dimeric and secretory IgA assembly and characterisation
- Mucosal transport and transcytosis assays including pIgR-mediated transport
- Effector-function profiling including FcγR activity, ADCC, ADCC and cytokine release
- Antigen-binding and cell-surface assays using high-throughput flow cytometry
- Pharmacokinetic and recycling assays including FcRn-based transport studies
- High-throughput IgA analytics across plate-, bead- and flow-based formats

Our partners

Monash Institute of Pharmaceutical Sciences
Charles Sturt University

BioNTech
Yale University

Invest with us



Jen Barnes
Director, Commercialisation and Research Translation; Director, Burnet Diagnostics Initiative
jennifer.barnes@burnet.edu.au



Carli Roulston
Head of Commercial Ventures
carli.roulston@burnet.edu.au

Office address: 85 Commercial Road, Melbourne, Victoria, 3004 ph: + 61 3 9282 2111



burnet.edu.au